David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk.
David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech.
David Stermanon
Analyst Articles
To make money in stocks, you need to focus on companies BEFORE everyone else does. It’s not easy to do… and often times it means buying stocks that are out of favor with the general market. But… Read More
It’s been four years, but it feels to be a lot longer than that. The U.S. housing sector started to quickly deteriorate in the spring of 2008, and though many hoped industry conditions would improve in a year or two, we’re still waiting for signs of life. And looking more… Read More
The market gets it right about 90% of the time. That’s been my experience with stocks that take a big hit or post a big rally. The other 10% of the time: the market reaction appears simply misplaced, and investors need to be patient and wait for logic… Read More
Investing in an undervalued high-growth play brings an inherent challenge. Shares are usually undervalued because the near-term growth prospects aren’t as bright as the long-term prospects. This was the biggest risk factor I laid out when I added Cree Inc. (Nasdaq: CREE) to my $100,000 Real-Money Portfolio. Read More
Here are two numbers to consider: 25% and -60%. These numbers should be moving in tandem, so there’s a really good chance the positive number will be sucked back down by the negative number. I’m talking about the stunning rally for dry-bulk shipping stocks and the sharp… Read More
The investing phrase “Growth at a Reasonable Price,” or GARP for short, likely sums up the ideal backdrop for many investors. Yet many stocks right now appear to possess fairly dim growth prospects and really only appeal to value-oriented investors. Indeed, I added toy maker Hasbro (NYSE: HAS) to… Read More
It was bound to happen. When I first began looking at stocks to add to my $100,000 Real-Money Portfolio, I knew I’d eventually come to a crossroads where I might have a holding that didn’t quite turn out how I’d hoped (or at least not yet), and I’d be faced… Read More
Every few weeks, another major manufacturer announces plans to shut down production in China and bring jobs closer to home. Some companies such as GE (NYSE: GE) aim to boost production in the United States (GE will make hot water heaters in Kentucky, for example). That’s because China is no… Read More
I’ve been thinking about biotech stocks a great deal lately. The sector seems to be trading much better in the early weeks of 2012, with a few spectacular gainers already in the bag and likely more to come. Yet investors are also well aware many biotech stocks simply flame out… Read More
The appeal of investing in turnaround stocks is very compelling. Some companies look to revamp products to re-invigorate sales growth. Others find ways to slash expenses and unlock major profit-margin gains. Still, others look to clean up a debt-laden… Read More
